uBiome

uBiome was an American biotechnology company founded in 2012 by Jessica Richman, Zachary Apte, and Will Ludington, scientists associated with the University of California, San Francisco's California Institute for Quantitative Biosciences. The company sought to make microbiome sequencing available to consumers, researchers, and clinicians by combining mailed biological-sampling kits with laboratory sequencing, surveys, comparative data, and software-based interpretation. Customers could order kits for samples from several body sites, including the gut, mouth, nose, skin, and genital tract. After collecting a sample with a swab, the customer completed a questionnaire and mailed the kit to uBiome. The company then analyzed the material and returned results that could be compared with its growing database of microbiome samples. The service was positioned at the intersection of direct-to-consumer testing, personal health data, citizen science, and research into the relationship between microorganisms and human health. uBiome's technical workflow initially involved polymerase chain reaction amplification of a section of the bacterial 16S ribosomal RNA gene, followed by sequencing and computational classification, generally at the genus level. Proprietary algorithms and web-based tools were used to interpret the sequence data and present comparisons to users. The company also developed mobile access to results, including an iOS application using Apple's ResearchKit framework. Its laboratory capabilities were supported by Clinical Laboratory Improvement Amendments certification in 2015 and accreditation from the College of American Pathologists in 2016. The company attracted attention from the technology and biotechnology communities through early crowdfunding, participation in Y Combinator, and investment from venture firms including Andreessen Horowitz and 8VC. It also promoted a citizen-science model in which customers contributed samples and associated survey information to a broader research dataset. That model generated interest but also raised questions concerning informed consent, institutional review, data quality, self-selection bias, and the appropriateness of crowdfunding a biotechnology venture. uBiome obtained institutional review board approval in 2013 and later offered a grant program intended to support microbiome sampling and analysis by researchers and citizen scientists. In 2019, the company's business came under severe pressure after the FBI searched its offices as part of an investigation into possible insurance fraud involving Medicare. Reports described allegations that patients had been billed repeatedly or without proper consent and that physicians had been pressured to authorize testing. Richman and Apte were placed on administrative leave while the board investigated. uBiome filed for Chapter 11 bankruptcy protection in September 2019 and converted the case to Chapter 7 liquidation less than a month later, bringing the operating business to an end. The legal issues continued after the shutdown. In 2021, the Securities and Exchange Commission charged Richman and Apte with defrauding investors, while federal criminal charges reportedly included conspiracy to commit fraud and money laundering. The founders were subsequently regarded by the FBI as fugitives. These events overshadowed uBiome's earlier scientific and entrepreneurial profile and led to comparisons with other controversial Silicon Valley biotechnology companies, including Theranos and 23andMe. uBiome is therefore best understood as a defunct microbiome-testing brand whose consumer-data and citizen-science ambitions were curtailed by regulatory, governance, and criminal-investigation problems.

uBiome was established in 2012 by Jessica Richman, Zachary Apte, and Will Ludington, scientists connected with the California Institute for Quantitative Biosciences. Its central idea was to use relatively accessible sampling kits and high-throughput sequencing to help consumers and researchers study the microorganisms living in and on the human body. The company developed a direct-to-consumer service in which customers collected samples from sites such as the gut, mouth, skin, nose, or genital tract, completed health-related surveys, and mailed the material to uBiome for laboratory processing. The company combined sequencing results with survey responses and a proprietary reference dataset. Early technical descriptions identified amplification and sequencing of a portion of the bacterial 16S ribosomal RNA gene as a core part of the workflow. The resulting data could be categorized and displayed through web software, allowing users to compare their microbiome profiles with other samples. Sequencing was reported to have been outsourced in the company's earlier period, with Illumina equipment identified in descriptions of the workflow. In 2015, uBiome introduced an iOS application using ResearchKit so users could access results on mobile devices. uBiome's model attracted both investment and criticism. It received mentoring and funding from Y Combinator and later attracted venture backing from Andreessen Horowitz and 8VC. Its use of customers as contributors to a large research dataset was presented as a form of citizen science. Bioethicists and biotechnology observers questioned whether customers had provided sufficiently informed consent, whether the data was affected by self-selection, and whether a commercial citizen-science program required institutional review. The company obtained institutional review board approval in July 2013. It subsequently offered a grant program for researchers and citizen scientists working on microbiome sampling and analysis; the Centers for Disease Control and Prevention was identified as a recipient in the first round. The company also pursued clinical and health-related credibility. It obtained Clinical Laboratory Improvement Amendments certification from the State of California in 2015 and College of American Pathologists accreditation in 2016. In 2018, Fast Company recognized uBiome in its list of innovative companies in data science, citing work involving the collection of microbiome data and development of tests related to HPV and sexually transmitted infections. The business collapsed in 2019. In April, FBI agents searched the company's offices as part of an investigation into possible Medicare-related insurance fraud. Accounts of the investigation alleged repeated or unauthorized billing of patients and pressure on doctors to approve tests. Richman and Apte were placed on administrative leave while the board examined the allegations. uBiome entered Chapter 11 bankruptcy in September 2019, then moved to Chapter 7 liquidation and shut down in October. The founders faced further legal action in 2021, when the SEC charged Richman and Apte with defrauding investors. They were also reported to face federal criminal charges involving conspiracy to commit fraud and money laundering. After relocating to Germany in 2020, the pair were considered fugitives by the FBI from 2021. The combination of an ambitious microbiome-data platform, unresolved ethical questions, alleged insurance misconduct, bankruptcy, and founder-related criminal proceedings made uBiome a prominent example of the risks surrounding consumer biotechnology and loosely regulated health-data businesses.

• 2021

  SEC and federal charges against co-founders

  [1]UBiomeen.wikipedia.org

  The SEC charged Richman and Apte with investor fraud, while federal criminal allegations included conspiracy to commit fraud and money laundering.

• 2019

  Federal search and bankruptcy

  [1]UBiomeen.wikipedia.org

  The FBI searched uBiome's offices in April; the company entered Chapter 11 in September and then Chapter 7 liquidation before shutting down.

• 2018

  Fast Company recognition

  [1]UBiomeen.wikipedia.org

  Fast Company included uBiome among companies recognized for innovation in data science, citing microbiome-data and testing work.

• 2016

  CAP accreditation

  [1]UBiomeen.wikipedia.org

  The company received accreditation from the College of American Pathologists.

• 2015

  CLIA certification and mobile results access

  [1]UBiomeen.wikipedia.org

  uBiome received CLIA certification in California and introduced an iOS application using ResearchKit for viewing microbiome results.

• 2013

  Institutional review board approval

  [1]UBiomeen.wikipedia.org

  The company obtained institutional review board approval after public discussion of consent and ethics issues surrounding its citizen-science model.

• 2012

  Company founded

  [1]UBiomeen.wikipedia.org

  Jessica Richman, Zachary Apte, and Will Ludington established uBiome to develop human-microbiome sequencing and analysis services.

A consumer-facing and research-oriented microbiome biotechnology platform combining mailed sampling kits, DNA sequencing, large-scale microbiome datasets, and software analysis.

• Consumer microbiome testing

  uBiome Explorer

  A mailed sampling-kit service through which customers collected biological material, completed a survey, and sent the sample to uBiome for sequencing. Results were presented through comparative software based on the company's microbiome dataset.

• Gut microbiome testing

  uBiome SmartGut

  A gut-focused microbiome testing offering built around mailed stool sampling and analysis. It was intended to provide users with information about their intestinal microbial profile and comparisons with other samples.

• Genital microbiome testing

  uBiome SmartJane

  A genital-microbiome testing service using customer-collected samples. It formed part of uBiome's broader effort to connect microbiome sequencing with reproductive and sexual-health research.

• Health-data software · 2015

  uBiome results platform

  Web and mobile software that allowed customers to review microbiome results, examine selected comparisons, and participate in a data-driven interpretation experience. An iOS version using ResearchKit was introduced in 2015.

• 2021

  Investor-fraud and federal criminal charges

  The SEC charged co-founders Jessica Richman and Zachary Apte with defrauding investors. They were also reported to face federal allegations involving conspiracy to commit fraud and money laundering.

  Source

• 2019

  Medicare billing investigation and FBI search

  The FBI searched uBiome's offices during an investigation into possible insurance fraud involving Medicare. Reported allegations included repeated or unauthorized patient billing and pressure on doctors to authorize tests.

  Source

• 2019

  Bankruptcy and liquidation

  Following the federal investigation and internal governance crisis, uBiome entered Chapter 11 bankruptcy and soon afterward Chapter 7 liquidation, ending the company's operations.

  Source

Read more

• 2015Microbiome research grant program

  United States

  The company offered grants intended to support researchers and citizen scientists conducting microbiome sampling and related analysis.

  Outcome. The first grant round included the Centers for Disease Control and Prevention among the identified recipients.

  Source
• 2013Citizen-science microbiome program

  United States

  uBiome promoted a model in which customers supplied biological samples and survey information that could contribute to a larger microbiome research dataset. The approach helped generate data at scale but prompted debate about consent, review procedures, and sampling bias.

  Outcome. The company obtained institutional review board approval in 2013 and continued developing consumer and research services.

  Source

• 2019

  Shift from reorganization to liquidationStrategy

  Background

  The company faced a federal investigation, leadership leave, and severe business disruption after the FBI search.

  Action taken

  uBiome first filed for Chapter 11 reorganization and then converted to Chapter 7 liquidation less than a month later.

  Aftermath

  The company shut down and its brand ceased operating.

  Source

1. 1UBiomeen.wikipedia.org